COVID-19 Coagulopathy.

Authors

Andrew Rettew, Department of Hematology & Oncology, Reading Hospital-Tower Health, West Reading, PAFollow
Ian Garrahy, Department of Hematology & Oncology, Reading Hospital-Tower Health, West Reading, PA
Shoja Rahimian, Department of Hematology & Oncology, Reading Hospital-Tower Health, West Reading, PAFollow
Rebecca Brown, Department of Hematology & Oncology, Reading Hospital-Tower Health, West Reading, PAFollow
Navdeep Sangha, Department of Hematology & Oncology, Reading Hospital-Tower Health, West Reading, PA

Document Type

Article

Publication Date

7-29-2024

Abstract

Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite being a primary respiratory illness, it is commonly complicated by systemic involvement of the vasculature leading to arterial and venous thrombosis. In this review, we will focus on the association between COVID-19 and thrombosis. We will highlight the pathophysiology of COVID-19 coagulopathy. The clinical manifestations of COVID-19 vasculopathy will be discussed with a focus on venous and arterial thromboembolic events. COVID-19 vasculopathy and disseminated intravascular coagulation (DIC) are distinguished within, as well as areas of controversy, such as "long COVID". Finally, the current professional guidelines on prevention and treatment of thrombosis associated with SARS-CoV-2 infection will be discussed.

Publication Title

Life (Basel)

Volume

14

Issue

8

First Page

953

Recommended Citation

Rettew, A., Garrahy, I., Rahimian, S., Brown, R., & Sangha, N. (2024). COVID-19 Coagulopathy.. Life (Basel), 14 (8), 953. https://doi.org/https://doi.org/10.3390%2Flife14080953